{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:06:44Z","timestamp":1790482004897,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112D64-002-MY2-2"],"award-info":[{"award-number":["V112D64-002-MY2-2"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jfma.2024.08.014","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:06:58Z","timestamp":1724144818000},"page":"746-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study"],"prefix":"10.1016","volume":"124","author":[{"given":"Hua-Hsi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-8853","authenticated-orcid":false,"given":"Wei-Ting","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2024.08.014_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.jfma.2024.08.014_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5468\/ogs.21116.e1","article-title":"Correction of funding information: the incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry","volume":"65","author":"Ha","year":"2022","journal-title":"Obstet. Gynecol. Sci."},{"key":"10.1016\/j.jfma.2024.08.014_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ygyno.2022.10.010","article-title":"Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: a meta-analysis","volume":"167","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib4","article-title":"Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan","volume":"6","author":"Hsu","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2024.08.014_bib5","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1245\/s10434-023-13757-0","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"30","author":"Gelissen","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15648","article-title":"HSPs drive dichotomous T-cell immune responses via DNA methylome remodelling in antigen presenting cells","volume":"8","author":"Kinner-Bibeau","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jfma.2024.08.014_bib7","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.3802\/jgo.2023.34.e72","article-title":"Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R)","volume":"34","author":"Yoo","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.jfma.2024.08.014_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO. Open"},{"key":"10.1016\/j.jfma.2024.08.014_bib9","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA. Surg."},{"key":"10.1016\/j.jfma.2024.08.014_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.08.014_bib12","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team Ovary Phase II Study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FRalpha-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2024.08.014_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1245\/s10434-021-10376-5","article-title":"HIPEC-induced acute kidney injury: a retrospective clinical study and preclinical model","volume":"29","author":"Liesenfeld","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib16","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s002800051093","article-title":"Successful management of microscopic residual disease in large bowel cancer","volume":"43","author":"Sugarbaker","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jfma.2024.08.014_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0959-8049(98)00375-X","article-title":"Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment","volume":"35","author":"Berthet","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jfma.2024.08.014_bib18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas. Dermosifiliogr. (Engl Ed)."},{"key":"10.1016\/j.jfma.2024.08.014_bib19","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","article-title":"Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study","volume":"21","author":"Le Brun","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jso.23688","article-title":"Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study","volume":"110","author":"Safra","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib21","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1245\/s10434-015-4991-4","article-title":"Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis","volume":"23","author":"Baiocchi","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bj.2021.10.003","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer","volume":"45","author":"Chen","year":"2022","journal-title":"Biomed J"},{"key":"10.1016\/j.jfma.2024.08.014_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/02656736.2020.1846793","article-title":"Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"37","author":"Chen","year":"2020","journal-title":"Int J Hyperther"},{"key":"10.1016\/j.jfma.2024.08.014_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jso.21732","article-title":"Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients","volume":"103","author":"Frenel","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2006.08.011","article-title":"A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma","volume":"104","author":"Elkas","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","article-title":"Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study","volume":"113","author":"Fagotti","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","article-title":"Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up","volume":"127","author":"Fagotti","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01212608","article-title":"Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells","volume":"123","author":"Rietbroek","year":"1997","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1096-9098(200102)76:2<106::AID-JSO1020>3.0.CO;2-E","article-title":"Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies","volume":"76","author":"Pestieau","year":"2001","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib30","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"Piccart","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2024.08.014_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14740338.2.6.597","article-title":"Toxicities of the platinum antineoplastic agents","volume":"2","author":"Markman","year":"2003","journal-title":"Expet Opin Drug Saf"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624003826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624003826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:37:49Z","timestamp":1753576669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624003826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0929664624003826"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.08.014","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}